

Q3 2025 *Results*



- The growth momentum we saw in Q3 confirms continued sales and earnings progress and positions us well to achieve our full-year guidance. Our pipeline delivered important milestones for patients this quarter, including the approval of new and differentiated medicines, in the US for the rare disease immune thrombocytopenia and in China to delay onset of stage 3, type 1 diabetes. •

Paul Hudson

Chief Executive Officer, Sanofi

Q3 2025 Company Sales

€12.4bn

+7.0% at constant exchange rates

+2.3% on a reported basis

Q3 2025 Business Earnings Per Share

€2.91

+13.2% at constant exchange rates

+7.0% on a reported basis

Sales by Category



Dupixent

€4.2bn



Pharma launches

€1.0bn



Vaccines

€3.4bn



Other medicines

€3.9bn

sanofi

Q3 2025 *Results*

Sales by Geography

US
€6.8bn

Europe
€2.6bn

Rest of the World
€3.0bn



Strong Pipeline Progress

- **2** regulatory approvals in the US and China.
- **2** positive phase 3 readouts in atopic dermatitis and influenza.
- **8** regulatory submission acceptances in the US, Europe, Japan and China.



Sustainability

Global Health Unit: **one million patients** have now received treatments for non-communicable diseases since 2021.

For further information on Q3 2025 results and definitions of financial indicators, please refer to the press release issued on October 24, 2025 at: www.sanofi.com/en/investors